Earvin “Magic” Johnson to Serve as Grand Marshal; Theme Celebrates “The Magic in Teamwork” as Viewers Experience the Grandeur of one of America's Most Beloved Traditions, January 1, Live from Pasadena, California Great American Mediatoday proudly announced it will serve as the national linear, digital, and streaming home to the 137th Rose Parade® presented by […]
Nyxoah Reports Third Quarter 2025 Financial and Operating Results GlobeNewswire November 13, 2025 REGULATED INFORMATION Nyxoah Reports Third Quarter 2025 Financial and Operating Results US launch off to a strong start. First commercial Genio implants completed with widespread payer coverage drives initial revenue. Mont-Saint-Guibert, Belgium – November 13, 2025, 10:10pm CET / 4:10 pm ET
Conference call to discuss financial and operational results scheduled for Friday, November 14 at 8:30 a.m. U.S. Eastern Time VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announces financial results and a business update for the third quarter ended September 30, 2025. Volition management will host a conference call tomorrow, November 14
Smartkem (Nasdaq: SMTK), which is seeking to change the world of electronics with a new class of transistor technology, today provides a business update and reports its financial results for the three and nine months ended September 30, 2025. https://mma.prnewswire.com/media/2822344/Logo___Smartkem.jpg Third Quarter 2025 Highlights: — Signed a non-binding Letter of Intent with Jericho Energy Ventures
(NASDAQ:FIGR), NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) — Figure Technology Solutions (Nasdaq: FIGR), the leading blockchain-native capital marketplace for the origination, funding, sale and trading of tokenized assets, today announced financial results for the quarter ended September 30, 2025. “We recently completed our successful initial public offering and are pleased to report a strong
(NasdaqGM:ACRV), Advancement of ACR-368 in registrational-intent Phase 2b trial for the treatment of patients with endometrial cancer Preparing for initial clinical data disclosure for ACR-2316 from the Phase 1 trial in AP3-prioritized solid tumor types Expanding power of Generative Phosphoproteomics AP3 supersedes conventional target-centric drug discovery, yielding differentiated compounds with desired pathway effects Cash, cash
(NYSE:MAX), LOS ANGELES, Nov. 13, 2025 (GLOBE NEWSWIRE) — MediaAlpha, Inc. (NYSE: MAX), the leading marketing technology platform powering real-time customer acquisition for the insurance industry, today announced the appointment of Ramon Jones to its Board of Directors, effective November 10, 2025. Mr. Jones brings more than two decades of property and casualty (P&C) insurance
(NASDAQ:ORIC), Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential best-in-class efficacy and safety Bolstered leadership team with the appointment of Kevin Brodbeck, PhD, as Chief Technical Officer to further support ORIC's transition to potential late-stage development Cash and investments of approximately $413 million
Figure Technology Solutions Reports Third Quarter 2025 Results GlobeNewswire November 13, 2025 NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) — Figure Technology Solutions (Nasdaq: FIGR), the leading blockchain-native capital marketplace for the origination, funding, sale and trading of tokenized assets, today announced financial results for the quarter ended September 30, 2025. “We recently completed our
Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights GlobeNewswire November 13, 2025 Advancement of ACR-368 in registrational-intent Phase 2b trial for the treatment of patients with endometrial cancer Preparing for initial clinical data disclosure for ACR-2316 from the Phase 1 trial in AP3-prioritized solid tumor types Expanding power of Generative Phosphoproteomics AP3